Treatment News

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R)

4.5 from 2 votes
Wednesday, October 11, 2017

PASADENA, Calif. - Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for the treatment of alpha-1 liver disease that uses Arrowhead's TRiMTM technology, at The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on October 20-24, 2017, in Washington, DC.

Poster Presentation:

Subcutaneous delivery of a RNA interference (RNAi) therapeutic candidate for alpha-1 antitrypsin deficiency (AATD)-related liver disease produces deep and prolonged knockdown of plasma AAT

Publication Number: LB-21
Session: Late-Breaking Poster Session
Session Date and Time: October 23, 2017 from 8:00 AM to 5:30 PM
Authors: Christine I. Wooddell, et al.

Additional details including presentation abstracts can be found on the AASLD website at A copy of presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after the presentation concludes.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit

Source: Arrowhead Pharmaceuticals, Inc.
4.5 from 2 votes
Free Newsletter